Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes

ConclusionsResults suggest that routes of administration cannot be compared using only the simplest descriptions (e.g., oral versus injectable). Dose frequency and specific details of the treatment process administration had an impact on patient preference and health state utilities. The utilities estimated in this study may be useful in cost-utility models comparing these treatments for T2D. Results also suggest that it may be helpful to consider patient preferences for treatment process when selecting medications for patients in clinical settings.
Source: Quality of Life Research - Category: Health Management Source Type: research